BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 26854026)

  • 1. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.
    Koschmieder S; Mughal TI; Hasselbalch HC; Barosi G; Valent P; Kiladjian JJ; Jeryczynski G; Gisslinger H; Jutzi JS; Pahl HL; Hehlmann R; Maria Vannucchi A; Cervantes F; Silver RT; Barbui T
    Leukemia; 2016 May; 30(5):1018-24. PubMed ID: 26854026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms.
    Chatain N; Koschmieder S; Jost E
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32806517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm.
    Fleischman AG
    Mediators Inflamm; 2015; 2015():606819. PubMed ID: 26538830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms.
    Prick J; de Haan G; Green AR; Kent DG
    Exp Hematol; 2014 Oct; 42(10):841-51. PubMed ID: 25201757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
    Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
    Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development.
    Andersen M; Sajid Z; Pedersen RK; Gudmand-Hoeyer J; Ellervik C; Skov V; Kjær L; Pallisgaard N; Kruse TA; Thomassen M; Troelsen J; Hasselbalch HC; Ottesen JT
    PLoS One; 2017; 12(8):e0183620. PubMed ID: 28859112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
    Sun T; Zhang L
    Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
    Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomics of MPN progression.
    Patel AA; Odenike O
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):440-449. PubMed ID: 33275731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remodeling the Bone Marrow Microenvironment - A Proposal for Targeting Pro-inflammatory Contributors in MPN.
    Jutzi JS; Mullally A
    Front Immunol; 2020; 11():2093. PubMed ID: 32983162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?
    Chen E; Mullally A
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):268-76. PubMed ID: 25696866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in understanding myelofibrosis and essential thrombocythemia.
    Vainchenker W; Constantinescu SN; Plo I
    F1000Res; 2016; 5():. PubMed ID: 27134742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An immune dysregulation in MPN.
    Barosi G
    Curr Hematol Malig Rep; 2014 Dec; 9(4):331-9. PubMed ID: 25139710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies].
    Takenaka K
    Rinsho Ketsueki; 2016; 57(10):1944-1955. PubMed ID: 27725592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolving genomic landscape of myeloproliferative neoplasms.
    Nangalia J; Green TR
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):287-96. PubMed ID: 25696868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms.
    Pandey R; Kapur R
    Mol Cancer; 2015 Jun; 14():118. PubMed ID: 26062813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Microenvironment in Myeloproliferative Neoplasms.
    Ramanathan G; Fleischman AG
    Hematol Oncol Clin North Am; 2021 Apr; 35(2):205-216. PubMed ID: 33641864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of mutation on diagnosis, risk stratification, and treatment decisions in Philadelphia-negative myeloproliferative neoplasms].
    Kirito K
    Rinsho Ketsueki; 2017; 58(10):1931-1940. PubMed ID: 28978835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms.
    Wiśniewska-Chudy E; Szylberg Ł; Dworacki G; Mizera-Nyczak E; Marszałek A
    Oncol Rep; 2017 Apr; 37(4):2295-2307. PubMed ID: 28260027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.